4月15日,专注于肿瘤及自身免疫疾病抗体药物研发的映恩生物正式登陆港交所,发行价为每股94.6港元。此次上市全球发售净筹资约15.13亿港元,资金将用于推动其创新药管线研发。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.